Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 118741913 | 11874191 | 3 | F | 20160725 | 20151229 | 20160802 | EXP | CN-ROCHE-1684056 | ROCHE | SHI Z, TANG X, WENG J, SHEN Q, CHEN X, CHEN J AND ZHUANG J RITUXIMAB PLUS REDUCED-DOSE CYCLOPHOSPHAMIDE, DOXORUBICIN, VINCRISTINE AND PREDNISONE (RD R-CHOP) CHEMOTHERAPY IS FEASIBLE FOR VERY ELDERLY PATIENTS (MORE THAN OR EQUAL TO 80 YEARS) WITH B-CELL LYMPHOMA: ANALYSIS OF TREATMENT OUTCOME. JOURNAL OF CHEMOTHERAPY 2016 JUN 17;:1-7. | 0.00 | Y | 0.00000 | 20160802 | MD | CN | CN |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 118741913 | 11874191 | 1 | PS | Rituximab | RITUXIMAB | 1 | Intravenous (not otherwise specified) | DAY 0 | U | 103705 | 375 | MG/M**2 | SOLUTION FOR INFUSION | Q3W | |||||
| 118741913 | 11874191 | 2 | SS | VINCRISTINE | VINCRISTINE | 1 | Intravenous (not otherwise specified) | ON DAY 1 | U | 0 | 1 | MG | Q3W | ||||||
| 118741913 | 11874191 | 3 | SS | PREDNISOLONE. | PREDNISOLONE | 1 | Intravenous (not otherwise specified) | U | 0 | INFUSION | Q3W | ||||||||
| 118741913 | 11874191 | 4 | SS | EPIRUBICIN | EPIRUBICIN | 1 | Intravenous (not otherwise specified) | U | 0 | 35 | MG/M**2 | Q3W | |||||||
| 118741913 | 11874191 | 5 | SS | CYCLOPHOSPHAMIDE. | CYCLOPHOSPHAMIDE | 1 | Intravenous (not otherwise specified) | U | 0 | 400 | MG/M**2 | Q3W |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 118741913 | 11874191 | 1 | B-cell lymphoma |
| 118741913 | 11874191 | 2 | B-cell lymphoma |
| 118741913 | 11874191 | 3 | B-cell lymphoma |
| 118741913 | 11874191 | 4 | B-cell lymphoma |
| 118741913 | 11874191 | 5 | B-cell lymphoma |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 118741913 | 11874191 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 118741913 | 11874191 | Bone marrow failure | |
| 118741913 | 11874191 | Hepatic function abnormal | |
| 118741913 | 11874191 | Neurotoxicity | |
| 118741913 | 11874191 | Renal failure |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |